MEGIN is delighted to be joining the Association of British HealthTech Industries (ABHI) UK Pavilion at Arab Health 2022, which is taking place from 24- 27 January in Dubai.
The exhibition – the largest event of its kind in the Middle East – will showcase more than 4,000 companies exhibiting their latest innovations to more than 130,000 healthcare professionals attending from 163 countries.
As Arab Health makes its return on the health technology calendar in January 2022, the Association of British HealthTech Industries (ABHI) will again be leading the UK’s most visible Pavilion of health technology companies. This year, a range of leading healthcare businesses, renowned hospital groups, and esteemed clinicians from world-leading clinics will be amongst the UK delegation travelling to the Middle East to showcase ‘the very best’ of UK HealthTech.
“MEGIN is delighted to be joining the ABHI UK Pavilion at Arab Health 2022, where we’ll be showcasing our world-leading Magnetoencephalography (MEG) technology. We aim to raise awareness for MEG technology and utilization in the region. We look forward to meeting new global partners at this year’s event,” announced John Fulford, Managing Director of MEGIN.
MEG is a non-invasive imaging technique that measures ongoing brain activity on a millisecond-by-millisecond basis, showing where in the brain the activity is produced. MEG is entirely non-invasive, silent, and with no applied magnetic fields, radiation, or injections of any kind.
MEGIN’s TRIUX™ neo provides access to patients for the most precise information currently available on the market for functional brain mapping.
Taking place at the Dubai World Trade Centre, the Arab Health Exhibition & Congress provides an unrivalled platform for the world’s leading manufacturers, wholesalers and distributors to meet the medical and scientific community from the Middle East and beyond.
Organised by the ABHI – the industry association for the health technology sector in the UK – the UK Pavilion will highlight how UK developments are transforming the lives of patients and clinicians across the globe.
Paul Benton, Managing Director, International, ABHI, said: “The UK is home to a vibrant and growing HealthTech sector and boasts some of the most innovative, evidence-based digital health solutions in the world today. Arab Health is the perfect platform to showcase these strengths on an international scale. Like other regions, the healthcare sector in the Middle East is facing rapidly growing demands for preventive care, and for innovative ways to reduce lifestyle-related diseases and ensure longer, healthier lives. We are proud to once again be hosting an outstanding line up of leading and innovative companies who are at the cutting-edge of healthcare innovation and technology and eager to showcase how their solutions can help tackle some of the biggest challenges in healthcare today.”
At Arab Health 2022, attendees will be able to see what makes UK health technology world-class by visiting the ABHI Pavilion, which will host a host of exhibitors showcasing the very best of UK HealthTech.
Throughout the event, MEGIN will be located in the ABHI UK Pavilion pod #2 (H2.H50C )
Arab Health 2022 will be taking place from 24-27January in Dubai, UAE.
For more information visit: https://ukhealthcarepavilion.com/events/arab-health-2022/
MEGIN is a neuroscience technology company based in Helsinki, Finland, with offices in the UK, USA, and Japan. The company is focused on developing innovative solutions for neuroimaging researchers as well as functional brain mapping for the presurgical evaluation of epilepsy, brain tumors or other lesions of the brain. For over 30 years, MEGIN has been the global leader in magnetoencephalography (MEG) technology. The TRIUX™ neo provides a non-invasive, real-time view of the brain’s specific neural activity with millimeter accuracy and millisecond resolution, providing the most precise information currently available on the market.
Copyright 2022 © MEGIN – TRIUX™ neo is available for sale in the European Union, UK, Japan, Canada, the United States, as well as certain other countries. In other geographical areas, contact your local MEGIN representative. TRIUX™ neo is approved for use to non-invasively localize regions of epileptic activity within the brain and, in conjunction with other diagnostic data, in neurosurgical planning. All other applications are research in nature.
ABHI is the UK’s leading industry association for health technology (HealthTech).
ABHI supports the HealthTech community to save and enhance lives. Members, including both multinationals and small and medium sized enterprises (SMEs), supply products from syringes and wound dressings to surgical robots and digitally enhanced technologies. We represent the industry to stakeholders, such as the government, NHS and regulators. HealthTech plays a key role in supporting delivery of healthcare and is a significant contributor to the UK’s economic growth. HealthTech is now the largest employer in the broader Life Sciences sector, employing 131,800 people in 4,060 companies, with a combined turnover of £25.6bn. The industry has enjoyed growth of around 5% in recent years. ABHI’s 320 members account for approximately 80% of the sector by value.